CompanyGraph
At a glance
- Depends onUpstream position: supplies 6 industries, depends on 3
- ScaleMarket cap is $2.26B, above the global median of $1.18B
Sign in to view price data.
Sign inThe reported statements, read against the company's own industry.
Financials view
Market Capitalization
1.66BGBP2.26B · vs all stocks (USD)
Revenue (TTM)
223.90MGBP305.69M · vs all stocks (USD)
Profit Margin
-64.85%vs Biotechnology peers
Beta
0.9120xvs all stocks
52-Week Change
-14.87%vs all stocks
Market Capitalization
1.66BGBP2.26B · vs all stocks (USD)
Enterprise Value
966.72MGBP1.32B · vs all stocks (USD)
Forward P/E
-18.41xvs Biotechnology peers
Price to Sales (TTM)
6.08xvs Biotechnology peers
Price to Book (MRQ)
2.91xvs Biotechnology peers
Enterprise to Revenue
4.32xvs Biotechnology peers
Enterprise to EBITDA
-8.36xvs Biotechnology peers
Profit Margin
-64.85%vs Biotechnology peers
Operating Margin
-48.69%vs Biotechnology peers
Return on Assets (TTM)
-12.02%vs Biotechnology peers
Return on Equity (TTM)
-27.67%vs Biotechnology peers
Revenue (TTM)
223.90MGBP305.69M · vs all stocks (USD)
Revenue per Share (TTM)
0.2330GBPUpdated Aug 22, 2026Quarterly Revenue Growth
19.40%vs Biotechnology peers
Gross Profit (TTM)
136.40MGBP186.23M · vs all stocks (USD)
EBITDA (TTM)
-115.60MGBP-157.83M · vs all stocks (USD)
Net Income (TTM)
-145.20MGBP-198.24M · vs all stocks (USD)
Operating Cash Flow (TTM)
-70.60MGBP-96.39M · vs all stocks (USD)
Levered Free Cash Flow (TTM)
-35.65MGBP-48.67M · vs all stocks (USD)
Trailing Annual Dividend Rate
0.00GBPUpdated Aug 22, 2026Trailing Annual Dividend Yield
0.00%vs all stocks
Payout Ratio
0.00%vs Biotechnology peers
EPS (Basic)
-0.1510GBPFY2025 · Dec 31, 2025EPS (Diluted)
-0.1510GBPFY2025 · Dec 31, 2025Basic Shares Outstanding
960.99MSharesFY2025 · Dec 31, 2025Diluted Shares Outstanding
960.99MSharesFY2025 · Dec 31, 2025Operating Cash Flow
-147.30MGBPFY2025 · Dec 31, 2025Free Cash Flow
-150.80MGBPFY2025 · Dec 31, 2025Cash & Cash Equivalents (End of Period)
181.10MGBPFY2025 · Dec 31, 2025Starting Profit (CF Statement)
-139.90MGBPFY2025 · Dec 31, 2025Stock-based Compensation
20.40MGBPFY2025 · Dec 31, 2025Other Non-cash Items
-23.30MGBPFY2025 · Dec 31, 2025Change in Accounts Receivable (CF)
-9.40MGBPFY2025 · Dec 31, 2025Change in Other Assets/Liabilities
4.90MGBPFY2025 · Dec 31, 2025Capital Expenditures
-3.50MGBPFY2025 · Dec 31, 2025Purchase of Investments
-49.90MGBPFY2025 · Dec 31, 2025Sale of Investments
144.10MGBPFY2025 · Dec 31, 2025Net Investing Cash Flow
90.70MGBPFY2025 · Dec 31, 2025Net Financing Cash Flow
6.70MGBPFY2025 · Dec 31, 2025Shares Outstanding
966.06MSharesUpdated Aug 22, 2026Float Shares
391.11MSharesUpdated Aug 22, 2026% Held by Insiders
43.17%vs all stocks
% Held by Institutions
34.16%vs all stocks
Total Cash (MRQ)
255.30MGBP348.56M · vs all stocks (USD)
Total Cash per Share (MRQ)
0.2640GBPUpdated Aug 22, 2026Total Debt (MRQ)
41.50MGBP56.66M · vs all stocks (USD)
Total Debt to Equity (MRQ)
0.0896xvs Biotechnology peers
Current Ratio (MRQ)
3.56xvs Biotechnology peers
Book Value per Share (MRQ)
0.4800GBPUpdated Aug 22, 2026Total Assets
622.50MGBP849.91M · vs all stocks (USD)
Total Current Assets
420.00MGBPFY2025 · Dec 31, 2025Total Liabilities
159.20MGBPFY2025 · Dec 31, 2025Total Non-current Assets
202.50MGBPFY2025 · Dec 31, 2025Total Non-current Liabilities
41.20MGBPFY2025 · Dec 31, 2025Total Current Liabilities
118.00MGBPFY2025 · Dec 31, 2025Cash & Cash Equivalents
181.10MGBPFY2025 · Dec 31, 2025Other Short-term Investments
74.20MGBPFY2025 · Dec 31, 2025Accounts Receivable
46.50MGBPFY2025 · Dec 31, 2025Inventory
81.50MGBPFY2025 · Dec 31, 2025Accounts Payable
18.40MGBPFY2025 · Dec 31, 2025Short-term Debt
5.20MGBPFY2025 · Dec 31, 2025Other Current Liabilities
-500.00KGBPFY2025 · Dec 31, 2025Long-term Debt
36.30MGBPFY2025 · Dec 31, 2025Other Non-current Liabilities
1.00MGBPFY2025 · Dec 31, 2025Common Stock (Book)
100.00KGBPFY2025 · Dec 31, 2025Retained Earnings
-550.90MGBPFY2025 · Dec 31, 2025Total Shareholders' Equity
463.30MGBP632.55M · vs all stocks (USD)
52-Week Low
95.61GBXUpdated Aug 22, 202652-Week High
208.00GBXUpdated Aug 22, 202652-Week Change
-14.87%vs all stocks
Beta
0.9120xvs all stocks
50-Day MA
118.18GBXUpdated Aug 22, 2026200-Day MA
126.92GBXUpdated Aug 22, 2026Avg 10-Day Volume
1.81MSharesUpdated Aug 22, 2026Avg 30-Day Volume
1.48MSharesUpdated Aug 22, 2026Diluted EPS (TTM)
-0.1500GBPUpdated Aug 22, 2026Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Supply Chain
Upstream position: supplies 6 industries, depends on 3Notable
Outgoing: 6.00Incoming: 3.00
Scale
Market cap is $2.26B, above the global median of $1.18BNotable
Market cap (USD): 2,263,584,712.815Global Median: 1,177,936,635.801
Companies that share the same coordination system — how they create, deliver, or capture value.
Zhejiang Jiuzhou Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Pfizer Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Adma Biologics Inc.
Tier 1ProductionApproval-Gated PipelineRuleFlow
HitGen Inc.
Tier 1ProductionApproval-Gated PipelineSenseMakingInterface
Establishment Labs Holdings Inc.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Verano Holdings Corp.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Jinyu Bio-Technology Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Acro Biosystems Co., Ltd.
Tier 1ProductionApproval-Gated PipelineSenseMakingFlow
Granules India Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Prestige Consumer Healthcare Inc.
Tier 1ProductionApproval-Gated PipelineRuleFlow